BPC October 09 update

Clinuvel CLVLY shares rise 44% following Tuesday's FDA Approval

Price and Volume Movers

Wednesday’s session lacked any significant price-moving news, with just a couple items noted below.

Ocugen, Inc., (NASDAQ: OCGN) announced its board has authorized a share repurchase program of up to $2m in value of its outstanding common stock. Stock will be purchased in the open market, subject to management discretion, board guidance and market conditions. Shares closed up 34% to $1.72.

Clinuvel Pharmaceuticals Limited (OTC: CLVLY) shares closed up 44% on the back of news released Tuesday that the FDA granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

Five Prime Therapeutics, Inc. (FPRX): $4.34; +18%.

Catabasis Pharmaceuticals, Inc. (CATB): $5.39; +16%.

Enlivex Therapeutics Ltd. (ENLV): $9.53; +12%.

Tyme Technologies, Inc. (TYME): $1.36; +7%.

Adaptimmune Therapeutics plc (ADAP): $1.08; +7%.

DECLINERS:

Caladrius Biosciences, Inc. (CLBS): $2.02; -15%.

Syndax Pharmaceuticals, Inc. (SNDX): $5.43; -12%.

Provention Bio, Inc. (PRVB): $5.99; -11%.

NextCure, Inc. (NXTC): $25.54; -10%.

Ovid Therapeutics Inc. (OVID): $2.19; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABBV – AbbVie Inc.
Risankizumab ( LIMMITLESS )
Psoriasis

Phase 3 Phase 3 data presented at EADV October 10, 2019.
$110.1 billion

AGIO – Agios Pharmaceuticals Inc.
AG-270
Solid tumors

Phase 1 Phase 1 data to be presented at AACR-NCI-EORTC International Conference October 27, 2019, 11:50 a.m ET.
$2 billion

DERM – Dermira Inc.
Lebrikizumab
Atopic Dermatitis

Phase 3 Phase 3 trial initiation announced October 9, 2019. Top-line data due 1H 2021.
$288.9 million

MBIO – Mustang Bio Inc.
IL13Ralpha2-Targeted CAR-T and Nivolumab/ Ipilimumab
Glioblastoma

Phase 1 Phase 1 trial opening announced October 9, 2019.
$117.4 million